Daniele Santini

Research interests

Publications

• Anxiety and depression in adult cancer patients: ESMO Clinical Practice Guideline

  ESMO Open · 2023 · https://doi.org/10.1016/j.esmoop.2023.101155

• The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline

  Annals of Oncology · 2022 · https://doi.org/10.1016/j.annonc.2022.04.007

• Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

  Journal for ImmunoTherapy of Cancer · 2021 · https://doi.org/10.1136/jitc-2021-002421

• Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples

  Journal of Experimental & Clinical Cancer Research · 2020 · https://doi.org/10.1186/s13046-020-01601-2

• Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(19)30862-9

• Bone health in cancer: ESMO Clinical Practice Guidelines

  Annals of Oncology · 2020 · https://doi.org/10.1016/j.annonc.2020.07.019

• Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice

  Journal for ImmunoTherapy of Cancer · 2020 · https://doi.org/10.1136/jitc-2020-001361

• Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

  The Lancet Oncology · 2020 · https://doi.org/10.1016/s1470-2045(19)30862-9

• A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

  Journal for ImmunoTherapy of Cancer · 2019 · https://doi.org/10.1186/s40425-019-0527-y

• Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan

  JAMA Oncology · 2018 · https://doi.org/10.1001/jamaoncol.2018.5080

• Tissue invasion and metastasis: Molecular, biological and clinical perspectives

  Seminars in Cancer Biology · 2015 · https://doi.org/10.1016/j.semcancer.2015.03.008

• Management of cancer pain: ESMO Clinical Practice Guidelines

  Annals of Oncology · 2012 · https://doi.org/10.1093/annonc/mds233

• Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?

  Annals of Oncology · 2012 · https://doi.org/10.1093/annonc/mdr623

• Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

  The Lancet Oncology · 2010 · https://doi.org/10.1016/s1470-2045(10)70130-3

• KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer

  British Journal of Cancer · 2009 · https://doi.org/10.1038/sj.bjc.6605177

• PTEN Expression and KRAS Mutations on Primary Tumors and Metastases in the Prediction of Benefit From Cetuximab Plus Irinotecan for Patients With Metastatic Colorectal Cancer

  Journal of Clinical Oncology · 2009 · https://doi.org/10.1200/jco.2008.20.2796

• Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients.

  PubMed · 2003

• Pamidronate induces modifications of circulating angiogenetic factors in cancer patients.

  PubMed · 2002

Current projects

No projects listed.